COPD disease progression and airway inflammation: Uncoupled by smoking cessation

European Respiratory Journal

Volumn 26, Issue 5, 2005, Pages 764-766

  Ind, P W ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID;

ANTIGEN DETECTION; BEHAVIOR MODIFICATION; CAUSE OF DEATH; CELL COUNT; CELL TRANSPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; DISEASE ACTIVITY; DISEASE COURSE; EDITORIAL; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LUNG BIOPSY; MACROPHAGE; MORBIDITY; MORTALITY; NEUTROPHIL; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; SMOKING CESSATION; SOCIOECONOMICS; SPUTUM ANALYSIS; T LYMPHOCYTE;

DISEASE PROGRESSION; HUMANS; PNEUMONIA; PREVALENCE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; SMOKING CESSATION;

EID: 27744479637     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00102805     Document Type: Editorial

References (21)

1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-1276.
2. Global initiative for Chronic Obstructive Lung Disease. Global strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report, 2005. www.goldcopd.com. Date last accessed: September 7, 2005. Date last updated: 2005.
3. Sullivan AK, Simonian PL, Falta MT, et al. Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Am J Respir Crit Care Med 2005; 172: 590-596.
4. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
5. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645-1648.
6. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of an inhaled anticholinergic bronchodilator on the rate of decline in FEV1. JAMA 1994; 272: 1497-1505.
7. Simmons MS, Connett JE, Nides MA, et al. Smoking reduction and the rate of decline in FEV1: results from the Lung Health Study. Eur Respir J 2005; 25: 1011-1017.
8. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not exsmokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 358-364.
9. Anthonisen NR, Lindgren PG, Tashkin DP, et al. Bronchodilator response in the lung health study over 11 years. Eur Respir J 2005; 26: 45-51.
10. Willemse BWM, ten Hacken NHT, Rutgers B, Lesman-Leegte IGAT, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005; 26: 835-845.
11. Willemse BW, ten Hacken NH, Rutgers B, et al. Smoking cessation improves both direct and indirect airways hyperresponsiveness in COPD. Eur Respir J 2004; 24: 391-396.
12. Wise RA, Kanner RE, Lindgren P, et al. The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD, the Lung Health Study. Chest 2003; 124: 449-458.
13. Willemse BW, Postma DS, Timens W, et al. The impact of smoking cessation on respiratory symptoms, lung function, airways hyperresponsiveness and inflammation. Eur Respir J 2004; 23: 464-476.
14. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55: 12-18.
15. Laperre TS, Postma DS, Gosman MM, et al. Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax 2005; Epub ahead of print.
16. Jones HA, Marino PS, Shakur BH, Morrell NW. In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma. Eur Respir J 2003; 21: 567-573.
17. Agusti A, MacNee W, Donalson K, Cosio M. Hypothesis: does COPD have an autoimmune component? Thorax 2003; 58: 832-834.
18. Hodge S, Hodge G, Holmes M, et al. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J 2005; 25: 447-454.
19. Cosio MG. Autoimmunity, T-cells and STA-4 in the pathogenesis of chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 3-5.
20. Hattotuwa KL, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. A double-blind, placebo controlled biopsy study. Am J Respir Crit Care Med 2002; 165: 1592-1596.
21. Pauwels RA, Lofdahl C-G, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-1953.